Clinical Trials Logo

Neoplastic Cells, Circulating clinical trials

View clinical trials related to Neoplastic Cells, Circulating.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06391892 Recruiting - Pancreatic Cancer Clinical Trials

Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery

LIQUIPANC
Start date: January 11, 2024
Phase: Phase 3
Study type: Interventional

This study evaluates the clinical prognostic impact (on DFS and OS) of liquid biopsy guided treatment vs. standard of care (physicians choice) in localized pancreatic cancer (despite because of CA 19-9 levels and computed tomography, upfront surgery is recommended by tumor board). ctDNA positive patients will receive neoadjvuant chemotherapy at current gold standard physicians choice instead of upfront surgery, because of assumed high biological risk for early recurrence.

NCT ID: NCT06314997 Recruiting - Clinical trials for Recurrence Free Survival

Dynamic Changes in Circulating Tumour Cells Protein Expression

Liquid-DRER2
Start date: January 14, 2019
Phase: Phase 2
Study type: Interventional

This multicenter study, randomized, controlled of blood-based biomarker-driven targhet therapy. Patients were selectedm( at Hospital San Giovanni and Celio in Rome) according to CTCs results ( CTCs-guided managment performed at University Magna Graecia) or managed by the treating clinician according to standard pathological criteria (standard management). The participants were assigned to trial groups with the use of block randomization stratified according to the enrolling center location metropolitan) and tumor stage (T3 or T4).

NCT ID: NCT06068348 Recruiting - Clinical trials for Circulating Tumor Cells

Liquid Biopsy Collection Study

Start date: October 7, 2021
Phase:
Study type: Observational

The purpose of this study is to develop a liquid biopsy approach for detection of circulating tumor cells (CTC) that could be used in place of the more invasive and potentially risky methods of tissue biopsy. The aims of the project are: (a) determine whether the Chaperonin-Containing TCP-1 (CCT) chaperonin can used to identify rare cancer cells in blood, and (b) establish whether the cancer cells detected using the CCT chaperonin for identification have invasive or metastatic potential.

NCT ID: NCT05988970 Recruiting - Lung Cancer Clinical Trials

Impact of Circadian Rhythm on the Spread of Circulating Tumor Cells in Lung Cancer Patients

SLEEP_CTC
Start date: January 29, 2024
Phase: N/A
Study type: Interventional

This is a prospective pilot study designed to demonstrate the impact of circadian rhythm on the spread of Circulating Tumor Cells (CTCs) in patients with Non- Small Cell Lung Cancer - NSCLC. 27 patients will be included in the study and will be followed for 12 months. For each included patient, blood samples will be collected before the anticancer treatment initiation.

NCT ID: NCT05964153 Recruiting - Glioma Clinical Trials

Analysis of Circulating DNA in Blood Samples of Glioma-affected Patients

Start date: January 31, 2023
Phase: N/A
Study type: Interventional

The present pilot study aims to investigate a new strategy in the liquid biopsy protocol for the diagnosis of gliomas based on the detection of circulating tumor DNA in the blood of patients with brain lesions compatible with this type of tumor. In order to increase the sensitivity of the technique, the investigators will work with raw blood samples through minimally invasive procedures. The subsequent analysis will be done with digital PCR, due to its low detection limit. The mutational results of each patient's samples will be compared with those obtained from the corresponding tissue biopsies. This step will allow the team to determine the robustness and reliability of the liquid biopsy. The grading of the tumor, as well as the confirmation of the diagnosis, will be obtained from the histological data. With the inclusion of more patients in the future, and with the optimization of the mutations investigated, the investigators want to standardize the protocol for the diagnosis of gliomas with liquid biopsy. This technique is less invasive than current surgical procedures used for diagnosis. In addition, using fewer hospital resources should allow a more accurate and rapid diagnosis of the pathology, and therefore, start the more personalized therapeutic stage earlier.

NCT ID: NCT05947188 Recruiting - Prostate Cancer Clinical Trials

Circulating Tumor Cells and mpMRI for Non-invasive Diagnosis of Prostate Cancer(CMNDPC)

CMNDPC
Start date: November 1, 2023
Phase: N/A
Study type: Interventional

This trial is a prospective, multicentre, diagnostic study. This study aims to evaluation the early diagnostic ability of circulating tumor cells plus multimodal MRI for prostate cancer.

NCT ID: NCT05815082 Recruiting - Colorectal Cancer Clinical Trials

ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer

Start date: February 20, 2023
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to compare in resectable colorectal cancer liver metastasis patients.The main question it aims to answer is whether the 3-year progression-free survival rate (PFS) of "watching and waiting" is non-inferior to adjuvant chemotherapy in postoperative ctDNA-negative resectable colorectal cancer liver metastasis patients.Participants will undergo ctDNA testing after resection of colorectal cancer liver metastasis, and will be randomly assigned to receive adjuvant chemotherapy or "watching and waiting" treatment strategy. The researchers will compare the outcomes between the two groups to see if the PFS between the two groups is similar.

NCT ID: NCT05797077 Recruiting - Colorectal Cancer Clinical Trials

Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA

Start date: February 20, 2023
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to compare in resectable liver metastases colorectal cancer patients.The main question it aims to answer is to investigate whether the progression-free survival (PFS) of resectable colorectal liver metastasis (CRLM) patients with positive ctDNA after surgery is superior with the combination of adjuvant chemotherapy and maintenance therapy compared to adjuvant chemotherapy alone.

NCT ID: NCT05752357 Recruiting - Carcinoma Clinical Trials

The Role of Pre-operative and Post-operative Circulating Tumor Cells in Gastric Cancer.

Start date: September 1, 2021
Phase:
Study type: Observational [Patient Registry]

In resectable gastric cancer participants who received curative surgery, to early and more accurately detect peritoneal carcinomatosis or occult metastasis is important. Also, investigators will look at CTC numbers in different timings after operation, to investigate the possibility of early detection for peritoneal carcinomatosis or occult metastasis. Also, this study will correlate the relationship of CTC and participants' survival.

NCT ID: NCT05662345 Recruiting - Clinical trials for Metastatic Breast Cancer

ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC)

ACT-MBC
Start date: December 12, 2022
Phase:
Study type: Observational

ACT-MBC prospectively assesses the impact of CTCs on treatment decisions, response assessment and prognosis in MBC patients.